Pacific Edge (NZE:PEB, ASX:PEB) said the Medicare coverage for its flagship Cxbladder test has been extended by two months to Thursday, April 24, according to a Monday filing with the New Zealand and Australian bourses.
Last Jan. 22, the cancer diagnostics company disclosed plans to seek a preliminary injunction in the US relating to the removal of Cxbladder test from the coverage of Medicare contractor, Novitas.
Pacific Edge's shares were up 7% in New Zealand and 10% in Australia.